Hanna John Walter JR sold $4.5M of CDNA

Hanna John Walter JR (President and CEO) sold 118,000 shares of CareDx, Inc. (CDNA) at an average of $37.79 ($36.11–$39.01, $4.46M total) across 2 trades on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanna John Walter JR
Published Jul 17, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan, which generally lowers the informational content versus discretionary selling.

02

Market read

This is a primary-source insider sale disclosure; it may slightly influence sentiment but is unlikely to change valuation absent additional fundamental news.

03

What to watch

The filing does not disclose new company fundamentals; traders should avoid extrapolating the sale into guidance or business deterioration without corroborating news.

Relevance 5/10Novelty 4/10Timing: after-hours, following the Form 4 filing on 2026-07-17

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA) by its CEO/President.

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CEO and President Hanna John Walter Jr sold 118,000 shares in open-market transactions totaling about $4.46M, per Form 4 filed today.

Expected impact

Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction disclosure, but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider activity without operational or financial disclosures.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • CareDx, Inc.

    Company whose insider transaction is disclosed on Form 4 (CDNA).

  • Hanna John Walter Jr

    President and CEO who sold 118,000 shares in open-market transactions.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, indicating the trades were scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.